Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2- early breast cancer

Last Updated: Friday, February 7, 2025

In a clinical review, researchers evaluated recent data—including data from the NATALEE and monarchE trials—on CDK4/6 inhibition in early-stage HR+ HER2- breast cancer. The review compares differences in patient selection, treatment duration, endocrine backbone therapy, and other study details among these recently published studies.

Drugs

Radiographics

Breast cancer surveillance in patients with a personal history of breast cancer: Updates and controversies

Frontiers in Oncology

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review

Journal of Clinical Oncology

Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Seminars in Nuclear Medicine

AI in breast cancer imaging: An update and future trends

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

HR+ HER2- Breast Cancer Resource Center